| Identification | Back Directory | [Name]
LY-364947 | [CAS]
396129-53-6 | [Synonyms]
CS-576
Y364947
E 616451
LY-364947
HTS 466284
LY-364947, >=98%
LY 364947;LY-364947
LY-364947 USP/EP/BP
LY364947(HTS 466284)
LY-364947, 396129-53-6
TGF-β RI Kinase Inhibitor
LY-364947?,HTS 466284, >98%
LY 364947;LY364947;HTS466284
LY364947;HTS466284; LY-364947
[3-(Pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole
4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]-quinoline
Quinoline, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-
4-[(3-Pyridin-2-yl)-1H-pyrazol-4-yl)]quinoline 95+%
TGF-β RI Kinase Inhibitor - CAS 396129-53-6 - Calbiochem
Transforming Growth Factor-β Type I Receptor Kinase Inhibitor
LY 364947 4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]quinoline
2-[4-(Quinolin-4-yl)-1H-pyrazol-3-yl]pyridine, 3-(Pyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazole
4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]quinoline E 616451 | [Molecular Formula]
C17H12N4 | [MDL Number]
MFCD00800758 | [MOL File]
396129-53-6.mol | [Molecular Weight]
272.31 |
| Chemical Properties | Back Directory | [Melting point ]
>230℃ (dec.) | [Boiling point ]
490.8±45.0 °C(Predicted) | [density ]
1.283±0.06 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
DMSO: soluble2mg/mL, clear | [form ]
powder | [pka]
8.94±0.50(Predicted) | [color ]
white to beige | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. | [InChI]
InChI=1S/C17H12N4/c1-2-6-15-13(5-1)12(8-10-19-15)14-11-20-21-17(14)16-7-3-4-9-18-16/h1-11H,(H,20,21) | [InChIKey]
IBCXZJCWDGCXQT-UHFFFAOYSA-N | [SMILES]
N1C2C(=CC=CC=2)C(C2=CNN=C2C2=NC=CC=C2)=CC=1 |
| Hazard Information | Back Directory | [Description]
LY-364947 (396129-53-6) is a selective ALK5 inhibitor, IC50 = 59, 400 and 1400 nM for TGF-β RI, TGF-β RII and MLK-7K, respectively.1 Inhibits Smad2 phosphorylation induced by TGF-β as well as fibronectin expression and MDA-MB-231 cell invasion.2 LY-364947 abolishes resistance of glioblastoma-initiating cells to radiation.3?Cell permeable. | [Uses]
Cell permeable, potent, selective and ATP-competitive inhibitor of TGF-β RI kinase (IC50=51nM). Displays ~15-fold greater selectivity over p38α MAPK (IC50=740nM). Inhibits TGF-β-dependent cellular growth (IC50=89nM in NIH 3T3 mouse fibroblasts) and transcription activation (IC50=47nM in mink lung cells). Suppresses invasion of MDA-MB-231 breast cancer cells in a matrigel invasion assay. | [Definition]
ChEBI: LY 364947 is a member of the class of pyrazoles carrying pyridin-2-yl and quinolin-4-yl substituents at positions 3 and 4 respectively. It has a role as a TGFbeta receptor antagonist. It is a member of pyrazoles, a member of pyridines and a member of quinolines. | [Biological Activity]
Selective inhibitor of TGF- β type-I receptor (TGF- β RI, TGFR-I, T β R-I, ALK-5) (IC 50 values are 59, 400 and 1400 nM for TGR- β RI, TGF- β RII and MLK-7K respectively). Inhibits TGF- β -dependent luciferase production in mink lung cells (p3TP lux) and growth in mouse fibroblasts (NIH 3T3) (IC 50 values are 47 and 89 nM respectively). Suppresses invasion of MDA-MB-231 breast cancer cells in a matrigel invasion assay. | [Biochem/physiol Actions]
LY-364947 is a selective, ATP-competitive inhibitor of Transforming Growth Factor-β Type I receptor kinase (TGF-β RI, ALK5) with IC50 = 59 nM. It is much less potent at related kinases, with IC50 = 400 nM for TGF-β RII and IC50 = 1400 nM for mixed lineage kinase-7 (MLK-7), a kinase in the MAP kinase signal pathway and closely related to TGF-β RII. LY-364947 inhibits TGF-β-dependent cellular growth (IC50 = 81 nM) in NIH 3T3 mouse fibroblasts. | [in vitro]
ly364947 was quickly identified as a potent inhibitor (ic50= 51 nm) and was chosen as a platform for sar development. compounds were further evaluated as inhibitors of tgf-β-dependent luciferase production in mink lung cells (p3tp lux) and growth in mouse fibroblasts (nih 3t3) [1]. | [in vivo]
in a rat model of nmda-induced retinal degeneration, simultaneous injection of nmda and the tgf-β inhibitor ly364947 slightly but significantly attenuated the reduction in number of cells in the ganglion cell layer and almost completely prevented the enhancement of capillary degeneration. [3]. | [storage]
Store at RT | [References]
1) Sawyer?et al. (2003),?Synthesis and activity of new aryl-and hetero-aryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain; J. Med. Chem.,?46?3953
2) Shiou?et al. (2006),?Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta; J. Biol. Chem.,?281?33971
3) Hardee?et al. (2012),?Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β; Cancer Res.,?72?4119 |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
|